Table 3 Meta-analysis results of the association between BIM deletion polymorphism and progression-free and overall survivals.

From: The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy

Group

Progression-free survival

Overall survival

study(case)

HR(95%CI)

Adjusted HR (95%CI)

study(case)

HR(95%CI)

Adjusted HR (95%CI)

 

Fixed

Random

Fixed

Random

 

Fixed

Random

Fixed

Random

NSCLC

6 (839)

2.000 (1.629–2.455)

2.067 (1.591–2.685)

2.194 (1.710–2.814)

2.194 (1.710–2.814)

2 (216)

1.419 (0.893–2.256)

1.361 (0.559–3.315)

—

—

HCC

1 (89)

0.720 (0.364–1.422)

0.720 (0.364–1.422)

0.866 (0.408–1.837)

0.866 (0.408–1.837)

1 (89)

1.170 (0.740–1.850)

1.170 (0.740–1.850)

0.668 (0.300–1.500)

0.668 (0.300–1.500)

  1. Abbreviation: NSCLC: non-small cell lung cancer; HCC: hepatocellular cancer; HR: hazard ratio; 95%CI: 95% confidential interval.
Back to article page